BC PARTNERS takes majority stake in IGS GeboJagema
Context
Led by the international investment firm BC Partners alongside reinvesting consortium members Smile Invest and the executive management team, this definitive transaction secures a controlling majority stake in the Dutch tooling specialist IGS GeboJagema. Formally announced on June 9, 2025, the cross-border leveraged buyout reconfigures the target's existing shareholding structure to fuel its next phase of global expansion. Under the negotiated terms of the capital restructuring, the historical financial partner Smile Invest—which has backed the manufacturer over the past several years—will roll over a portion of its equity to retain a minority shareholding position. Conversely, the secondary financial shareholder, Rabo Private Equity, will completely liquidate its minority position and fully exit the business upon closing. The strategic rationale articulated by the acquiring private equity sponsor, steered locally by Managing Director Matthew Evans, centers on deploying institutional capital to accelerate the target's capacity to serve rapidly growing end markets. Specifically, the new ownership consortium aims to aggressively expand the manufacturer's presence within the high-demand GLP-1 segment and fund entry into adjacent healthcare verticals requiring high-precision molds. The integration roadmap heavily emphasizes continued organic expansion coupled with a targeted buy-and-build acquisition strategy designed to consolidate the fragmented healthcare toolmaking sector. For the target company, partnering with a transatlantic sponsor provides the operational scale and specialized pharmaceutical automation expertise necessary to elevate its commercial profile globally. To navigate the competitive transaction dynamics, the buy-side executive board mandated Lincoln International as its exclusive mergers and acquisitions advisor, with the advisory team led by Managing Director Sibert Meulenbelt contributing deep sector knowledge in the mold-making space. On the sell-side, the exiting and reinvesting shareholders, represented by Smile Invest Managing Partner Bart Cauberghe and Partner Ad Notenboom, engaged the investment bank Rothschild & Co to execute the comprehensive financial auction. The completion of this strategic capital transition remains strictly subject to the receipt of customary regulatory approvals and mandatory feedback from the competent workers council.
IGS GeboJagema, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level than the average currently observed in the Industry & Manufacturing sector (11.7x).
-> Deep-dive in Industry & Manufacturing market trends
Target
IGS GeboJagema is a globally focused provider of high‑precision injection moulding technology dedicated exclusively to the healthcare sector. The company designs and manufactures multi‑cavity moulds with ultra‑low tolerance specifications, enabling exact, repeatable and scalable production of medical devices. Its product portfolio serves drug‑delivery systems, ophthalmic lenses, diagnostic equipment and a range of healthcare consumables. By integrating Industry 4.0 automation, digital monitoring and standardized processes, IGS delivers tooling that meets the stringent regulatory and quality requirements of leading pharmaceutical and medical‑device manufacturers. Established in the mid‑twentieth century, the firm is headquartered in Eindhoven, the Netherlands, and operates a manufacturing facility in Peachtree City, Georgia, thereby providing a transatlantic footprint. IGS functions as a strategic partner to multinational pharma and device companies, supplying mission‑critical moulds that underpin the manufacture of high‑value therapeutic and diagnostic products. The organization’s value proposition rests on deep engineering expertise, vertical integration from design through production, and a commitment to continuous technical innovation within the niche of healthcare‑specific tooling.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Industrial Equipment
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2025 | DXP ENTERPRISES | MOORES PUMP & SERVICES | UNITED STATES | Valves, Pumps & Taps |
| 05/2025 | LATOUR CAPITAL | ROLLAKIN (BOLLIN / ROLLIN) | FRANCE | Components |
| 04/2025 | Eaton Fiber | Fibrebond | UNITED STATES | Electrical Equipment |
| 03/2025 | PIOVANGROUP | BHT | ITALY | Food & Beverage Lines |
| 03/2025 | ALFA LAVAL | FIVES ENERGY CRYOGENICS | FRANCE | Process Engineering & Production Lines |
| 03/2025 | PIOVANGROUP | MIX&CO | ITALY | Process Engineering & Production Lines |
| 01/2025 | WABTEC | EVIDENT INSPECTION TECHNOLOGIES | UNITED STATES | Instrumentation & Measurement |
| 12/2024 | JBT MAREL | MAREL | ICELAND | Food & Beverage Lines |
| 11/2024 | CRANE COMPANY | TECHNIFAB PRODUCTS | UNITED STATES | Valves, Pumps & Taps |
| 03/2023 | ALPHA PRIVATE EQUITY / PENINSULA CAPITAL | PRIMA INDUSTRIE | ITALY | Machine Tools |
REFERENCES
Valuation range: EV 300M - 700M EUR
Revenue range: 50M - 100M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IGS GeboJagema by BC PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: igs gebojagema
Acquirer: bc partners